Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
Ther Adv Psychopharmacol December 4, 2025 Charles Dodds, Rachelle Dawson, Alexander Lim et al. 3 citations
Psychedelic compounds such as ketamine, MDMA, and psilocybin show promise for treating post-traumatic stress disorder by modulating synaptic plasticity and enhancing memory processing and extinction. These interventions may overcome limitations of conventional therapies and, when combined with existing psychotherapies, produce rapid and lasting improvement in chronic symptoms. The review discusses how modern methods for predicting treatment response could enable personalized precision medicine approaches, using quantitative evidence to tailor psychedelic interventions to individual patients.